Radioactive drug trial offers new hope for tough prostate cancer
NCT ID NCT07381582
Summary
This early study is testing a new radioactive drug called 161Tb-LNC1011 for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to find the safest dose and see how the drug travels to and stays in tumors. Researchers will also check for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Mianyang Central Hospital
Mianyang, Sichuan, China
Contact Phone: •••-•••-••••
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.